Annals of the Rheumatic Diseases : Impact Factor & More
eISSN: 1468-2060pISSN: 0003-4967
Share this on:
Aims and Scope of Annals of the Rheumatic Diseases
The Annals of the Rheumatic Diseases is a peer-reviewed medical journal. It is co-owned by the BMJ Group and the European League Against Rheumatism and covers all aspects of rheumatology, including musculoskeletal conditions, arthritis, and connective tissue diseases. The journal publishes basic, clinical, and translational research and abstracts from conferences. The journal was established in 1939. It is available online by subscription and archived editions of the journal (older than one year) are available free of charge. Each issue, the editor-in-chief selects a paper to be published open access as an "Editors Choice". The editor-in-chief is Josef Smolen. Less
Key Metrics
CiteScore 
28.5
Eigenfactor
0.05 - 0.1
H-Index
272
Impact Factor
>= 25
Scite Index
0.88 5-Year SI
SJR
Q1Immunology
SNIP
5.22
Recommended pre-submission checks
Powered by 
Run standard language and technical checks to improve your manuscript – before you submit
Technical Compliance
Ensure manuscript complies with standard submission guidelines.
Language Quality
Improve clarity, grammar, and academic writing style.
A comprehensive report covering all these checks awaits you.
Topics Covered on Annals of the Rheumatic Diseases
Annals of the Rheumatic Diseases Journal Specifications
| Overview | |
| Publisher | BMJ PUBLISHING GROUP |
| Language | English |
| Frequency | Monthly |
| General Details | |
| Language | English |
| Frequency | Monthly |
| Publication Start Year | 1935 |
| Publisher URL | Visit website |
| Website URL | Visit website |
View less
Planning to publish in Annals of the Rheumatic Diseases ?
Upload your Manuscript to get
- Degree of match
- Common matching concepts
- Additional journal recommendations
Recently Published Papers in Annals of the Rheumatic Diseases
A pathogenic gut lipoglycan drives systemic thromboinflammation in lupus nephritis.
- 23 Apr 2027
- Annals of the rheumatic diseases
International expert consensus recommendations on standardised nomenclature of SSA/Ro (TROVE2/Ro60 and TRIM21/Ro52) autoantibodies in autoimmune diseases.
- 14 May 2026
- Annals of the rheumatic diseases
Thresholds for efficacy outcomes in psoriatic arthritis vary according to baseline disease activity but not according to prior tumour necrosis factor inhibitor treatment.
- 13 May 2026
- Annals of the rheumatic diseases
Broad screening of inflammation-associated proteins identifies serum CCL19 as a novel biomarker of disease activity in IgG4-related disease.
- 13 May 2026
- Annals of the rheumatic diseases
Anti-PAD4 antibodies link autoimmunity to PAD4 with CTL-associated rheumatoid arthritis.
- 12 May 2026
- Annals of the rheumatic diseases
Whole blood transcriptome profiling in patients treated with deucravacitinib and novel mechanistic insights into TYK2 inhibition in lupus: results from a post hoc analysis of the PAISLEY SLE phase 2 trial.
- 11 May 2026
- Annals of the rheumatic diseases
A pathogenic gut lipoglycan drives systemic thromboinflammation in lupus nephritis.
- 23 Apr 2027
- Annals of the rheumatic diseases
International expert consensus recommendations on standardised nomenclature of SSA/Ro (TROVE2/Ro60 and TRIM21/Ro52) autoantibodies in autoimmune diseases.
- 14 May 2026
- Annals of the rheumatic diseases
Thresholds for efficacy outcomes in psoriatic arthritis vary according to baseline disease activity but not according to prior tumour necrosis factor inhibitor treatment.
- 13 May 2026
- Annals of the rheumatic diseases
Broad screening of inflammation-associated proteins identifies serum CCL19 as a novel biomarker of disease activity in IgG4-related disease.
- 13 May 2026
- Annals of the rheumatic diseases
Anti-PAD4 antibodies link autoimmunity to PAD4 with CTL-associated rheumatoid arthritis.
- 12 May 2026
- Annals of the rheumatic diseases
Whole blood transcriptome profiling in patients treated with deucravacitinib and novel mechanistic insights into TYK2 inhibition in lupus: results from a post hoc analysis of the PAISLEY SLE phase 2 trial.
- 11 May 2026
- Annals of the rheumatic diseases
FAQs on Annals of the Rheumatic Diseases
How long has Annals of the Rheumatic Diseases been actively publishing? 
What is the publishing frequency of Annals of the Rheumatic Diseases?
How many articles did Annals of the Rheumatic Diseases publish last year?
What is the eISSN & pISSN for Annals of the Rheumatic Diseases?
What is Citescore for Annals of the Rheumatic Diseases?
What is the H Index for Annals of the Rheumatic Diseases ?
What is SNIP score for Annals of the Rheumatic Diseases?
What is the SJR for Annals of the Rheumatic Diseases?
Who is the publisher of Annals of the Rheumatic Diseases?
Check if your manuscript is a good match for
undefined
Upload your manuscript to get recommendations of journals
that have published papers similar to your manuscript
Drag and drop your file here
We accept manuscripts in English. File format: .doc and .docx | Maximum size: 10 MB | Word count: 200-300,000 words | File length: less than 100 pages
Do not have a manuscript right now? Use an abstract or summary
Your document is 100% secure & confidential We use 256-bit encryption for total security and
ISO/IEC 27001:2013 Certified
What all does the report include
01. Degree of Match
02. Common Topics
03. Additional
Recommendations
Recommendations